Michael Packert - ChemoMetec Head Production

All Insiders . Germany . 
Stock . ChemoMetec AS . Stakeholders . Insider . Michael Packert
CHY Stock  EUR 63.25  1.55  2.39%   

Insider

Michael Packert is Head Production of ChemoMetec AS
Phone45 48 13 10 20
Webhttps://chemometec.com

ChemoMetec Management Efficiency

The company has return on total asset (ROA) of 0.3117 % which means that it generated a profit of $0.3117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4858 %, meaning that it generated $0.4858 on every $100 dollars invested by stockholders. ChemoMetec's management efficiency ratios could be used to measure how well ChemoMetec manages its routine affairs as well as how well it operates its assets and liabilities.
ChemoMetec AS has accumulated 2.36 M in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. ChemoMetec AS has a current ratio of 3.32, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist ChemoMetec until it has trouble settling it off, either with new capital or with free cash flow. So, ChemoMetec's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ChemoMetec AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ChemoMetec to invest in growth at high rates of return. When we think about ChemoMetec's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Joseph DeProsperoDave Busters Entertainment
48
Matthew PalmieriUniversal Insurance Holdings
43
Robert PeedUnited Insurance Holdings
60
Michael QuartieriDave Busters Entertainment
55
Brendan MurphyUnited Utilities Group
53
Jason BurnsUniversal Insurance Holdings
43
Antonio GonzalezUnited Insurance Holdings
N/A
Philip AspinUnited Utilities Group
55
Louise BeardmoreUnited Utilities Group
N/A
Gary RopieckiUniversal Insurance Holdings
N/A
Michael PoloskeyUniversal Insurance Holdings
52
Brooke AdlerUnited Insurance Holdings
46
Cory HattonDave Busters Entertainment
N/A
Jane GilmoreUnited Utilities Group
N/A
Steven MogfordUnited Utilities Group
67
Bennett CPAUnited Insurance Holdings
52
Ruth HenshawUnited Utilities Group
N/A
John HenleyUnited Insurance Holdings
N/A
Adrienne McFarlandUnited Utilities Group
N/A
Steven KlohnDave Busters Entertainment
N/A
Robert LeeUnited Utilities Group
N/A
ChemoMetec AS engages in the development, production, and sale of analytical equipment for cell counting and analysis in Denmark, the United States, Canada, rest of Europe, and internationally. The company was founded in 1997 and is headquartered in Allerd, Denmark. CHEMOMETEC operates under Scientific Technical Instruments classification in Germany and is traded on Frankfurt Stock Exchange. It employs 147 people. ChemoMetec AS (CHY) is traded on Frankfurt Exchange in Germany and employs 162 people.

Management Performance

Return On Equity0.49
Return On Asset0.31

ChemoMetec AS Leadership Team

Elected by the shareholders, the ChemoMetec's board of directors comprises two types of representatives: ChemoMetec inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ChemoMetec. The board's role is to monitor ChemoMetec's management team and ensure that shareholders' interests are well served. ChemoMetec's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ChemoMetec's outside directors are responsible for providing unbiased perspectives on the board's policies.
Martin Behrens, Chief US
Christopher MSc, VP US
Michael Packert, Head Production
Steen Sondergaard, Chief Officer
Hans Glensbjerg, Vice COO
Lisbet Helles, Head Marketing
Sren Kjrulff, Head RD
Niels Nielsen, Chief Officer

ChemoMetec Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ChemoMetec a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.49
Return On Asset0.31
Profit Margin0.39 %
Operating Margin0.50 %
Current Valuation1.93 B
Shares Outstanding17.4 M
Shares Owned By Insiders10.87 %
Shares Owned By Institutions51.35 %
Price To Earning221.15 X
Price To Book40.66 X

Currently Active Assets on Macroaxis

TITANTitan Company Limited
UUnity Software
PAYCPaycom Soft
HBIHanesbrands
STLDSteel Dynamics

Other Information on Investing in ChemoMetec Stock

ChemoMetec financial ratios help investors to determine whether ChemoMetec Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ChemoMetec with respect to the benefits of owning ChemoMetec security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY